Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Donald McNeil

Allergy & Immunology Columbus, OH Medical Doctor

NPI 1134199300 CMS profile 452612

8080 Ravines Edge Ct, 200, Columbus, OH 43235

Open in the dashboard

General payments

$135,907

512 records reported · program years 2019–2025

Research payments

$11,527

Paid to them · 12 records reported · program years 2019–2025

Ownership & investment interest

$2,000

1 holding reported · through program year 2025

Research they led as principal investigator

$4,680,725 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Donald McNeil of Columbus, OH is reported in the CMS Open Payments database as having received $135,907 across 512 general payments and $11,527 in research payments paid to them. Separately, studies naming them as principal investigator received $4,680,725 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $2,000 across 1 holding.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 95th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $11,390 55
2024 General $23,540 78
2024 Research $2,250 9
2023 General $20,989 104
2022 General $43,989 105
2021 General $11,083 78
2020 General $3,474 18
2020 Research $2,525 1
2019 General $21,442 74
2019 Research $6,753 2
2024 Ownership $2,000 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Donald McNeil
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Donald McNeil were reported at $11,390. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Donald McNeil Allergy & Immunology median Middle half National median
2019 $21,442 $594 $163–$1,512 $163
2020 $3,474 $426 $106–$1,233 $114
2021 $11,083 $638 $157–$1,708 $132
2022 $43,989 $790 $205–$1,961 $149
2023 $20,989 $852 $220–$2,147 $160
2024 $23,540 $865 $203–$2,267 $164
2025 $11,390 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. BioCryst US Sales Co., LLC $57,919 60 payments
  2. Pharming Healthcare, Inc. $27,307 80 payments
  3. CSL Behring $16,647 38 payments
  4. BioCryst Pharmaceuticals, Inc. $8,315 25 payments
  5. AbbVie, Inc. $5,923 23 payments
  6. AstraZeneca Pharmaceuticals LP $3,837 69 payments
  7. Shire North American Group Inc $2,949 6 payments
  8. Genzyme Corporation $2,275 24 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $2,259 20 payments
  10. GC Biopharma USA, Inc. $2,035 3 payments
  11. Other $6,442 164 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $45,893 32 payments
  2. Consulting Fee $35,534 20 payments
  3. Honoraria $21,310 8 payments
  4. Travel and Lodging $19,087 56 payments
  5. Food and Beverage $13,841 389 payments
  6. Education $242 7 payments
Products named General payments · program years 2019–2025
  1. Orladeyo $50,142 58 payments
  2. RUCONEST $24,765 75 payments
  3. Haegarda $6,200 18 payments
  4. Andembry $5,457 7 payments
  5. JOENJA $2,542 5 payments
  6. ALYGLO $2,035 3 payments
  7. FASENRA $1,183 22 payments
  8. TEZSPIRE Inflammation $884 25 payments
  9. DUPIXENT $840 43 payments
  10. TEZSPIRE Respiratory $776 14 payments
  11. Other $4,664 169 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Eli Lilly and Company $9,278 3 payments
  2. Corcept Therapeutics $1,766 7 payments
  3. GlaxoSmithKline, LLC. $484 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

494

Median for Allergy/ Immunology: 449

Drug cost

$1,946,186

Median for Allergy/ Immunology: $169,700

Branded share of claims

46.8%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Icatibant Icatibant Acetate Brand 40 $684,836
Orladeyo Berotralstat Hydrochloride Brand 14 $575,089
Takhzyro Lanadelumab-Flyo Brand 13 $353,536
Gammaplex Immun Glob G(Igg)/Gly/Iga 0-50 Brand 17 $264,917
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 52 $37,816
Breo Ellipta Fluticasone/Vilanterol Brand 32 $15,768
Advair Diskus Fluticasone Propion/Salmeterol Brand 17 $3,929
Epinephrine Generic 21 $3,710
Ipratropium Bromide Generic 43 $1,749
Pilocarpine Hcl Generic 17 $1,445

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 21 billing codes

Paid by Medicare

$25,262

Medicare's payments for the services billed

Medicare patients

126

Average age 72

Services billed

1,632

79 women, 47 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 55%
COPD 28%
Diabetes 27%
Depression 26%
Ischemic heart disease 22%
Chronic kidney disease 20%
Osteoporosis 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RUCONEST
  • Pharming Healthcare, Inc. $4,555
$4,555 — —
TEZSPIRE
  • AstraZeneca Pharmaceuticals LP $163
  • Amgen Inc. $81
$244 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $241
$241 — —
Orladeyo
  • BioCryst US Sales Co., LLC $158
$158 14 —
FASENRA
  • AstraZeneca Pharmaceuticals LP $147
$147 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

524 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record